Tag Archives: Clinical

GrowPros

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

OTTAWA, Ontario, Oct. 26, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

Seizures

Cannabis Derivative Cannabidiol Reduces Seizures in Severe Epilepsy Disorder

NEW YORK, May 24, 2017 /Weed Wire/ – After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency 39 percent for patients with Dravet syndrome—a rare, severe form of epilepsy—in the first large-scale, randomized clinical trial for the compound.

MJIN_MAPS-Logo-Web

Statement on the Adequacy of Marijuana Provided by NIDA for Phase 2 Clinical Trials for PTSD in Veterans

PHOENIX, March 17, 2017 /Weed Wire/ — As of March 15, 2017, five participants have received marijuana (cannabis) provided by the National Institute on Drug Abuse (NIDA) in an ongoing Phase 2 clinical trial sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) at the Scottsdale Research Institute (SRI) in Phoenix, Ariz. MAPS is committed to sponsoring rigorous clinical research to develop cannabis into a prescription medicine through the Food and Drug Administration (FDA).

Zynerba

Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis

DEVON, Penn., March 13, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures.

Higher Ed in Cali: Two Universities Offering Medical Cannabis Education

Higher Ed in Cali: Two Universities Offering Medical Cannabis Education

With its Humboldt Institute for Interdisciplinary Marijuana Research, Humboldt State University in California has been at the academic forefront of marijuana since 2012, but other institutions of higher education in the state are starting to follow suit.


Top